Hims & Hers Health Inc: Growth Ambitions Accelerate Globally—But Profitability Is Moving the Wrong Way!

Hims & Hers’ first quarter highlights a company aggressively prioritizing scale, category expansion, and global platform leadership, even as near-term profitability compresses materially. Revenue increased 4% year over year to $608 million, while subscribers grew 9% to nearly 2.6 million, but adjusted EBITDA margin fell to 7% and GAAP net loss widened sharply as the company absorbed restructuring costs tied to its compounded GLP-1 transition and accelerated international investments. The core growth engine remains branded weight-loss expansion, where management is now onboarding more than 100,000 new subscribers monthly, supported by strong app engagement and elevated provider interaction levels that reinforce retention and cross-sell potential. Full-year revenue guidance was raised to $2.8–$3.0 billion, implying confidence in accelerating demand momentum, while EBITDA guidance of $275–$350 million reflects management’s expectation for significant second-half operating leverage as monthly shipment cohorts mature and marketing efficiency improves. International operations are also becoming increasingly strategic, with ZAVA outperforming expectations and the pending Eucalyptus acquisition expanding exposure across key global markets. Meanwhile, vertical integration initiatives in peptide manufacturing, AI-powered personalization, and closed-loop care infrastructure position the company to deepen monetization and customer retention over time. However, sustained margin pressure, elevated operating costs, regulatory uncertainty, and execution risk around international scaling remain central concerns. Can Hims & Hers successfully convert its explosive GLP-1 and international expansion momentum into a structurally profitable global digital healthcare platform before rising competitive and regulatory pressures erode its long-term economics?